CRISPR-based diagnostics as a specificity layer for the early detection of pancreatic cancer
Cancer Letters · 2026
DOI: 10.1016/j.canlet.2026.218851 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2026. Verfasst von Mafalda Angelica Rocco und 6 weiteren Autor:innen. Beteiligte Einrichtung: Sant'Anna School of Advanced Studies, Pisa, 56127, Italy; Fondazione Pisana per La Scienza ETS, Pisa, 56017, Italy; Laboratory of Medical Oncology, D…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Early Detection of Cancer, Biomarkers, Tumor, Carcinoma, Pancreatic Ductal. Die Arbeit nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione Pisa, KWF Kankerbestrijding, Associazione Italiana per la Ricerca sul Cancro.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy, largely because early-stage symptoms are non-specific and diagnosis is often delayed. Although liquid biopsies (LBs) offer a promising non-invasive strategy for early detection, their clinical translation is hindered by substantial analytical limitations. This review examines the current landscape of nucleic acid-based liquid biopsy biomarkers for PDAC detection. We evaluate key limitations of established diagnostic methodologies, including next-generation sequencing (NGS) and droplet digital PCR (ddPCR). In complex biofluids, these approaches may be confounded by background signal and amplification artifacts, particularly when applied for the detection of ultra-rare targets. To address this diagnostic gap, we discuss the role of CRISPR-based biosensing and bioassay not as a replacement but as an additional specificity layer within existing diagnostic workflows. In this framework, CRISPR technologies can act as sequence-specific molecular filters that introduce an active post-amplification validation step. Although pre-analytical limitations remain to be fully characterized, integrating CRISPR into the diagnostic workflow may contribute to a rapid, cost-effective, and highly specific framework for the early detection of PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sant'Anna School of Advanced Studies, Pisa, 56127, Italy; Fondazione Pisana per La Scienza ETS, Pisa, 56017, Italy; Laboratory of Medical Oncology, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC,…
- Laboratory of Medical Oncology, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit, Amsterdam, 1081 HZ, the Netherlands.
- Fondazione Pisana per La Scienza ETS, Pisa, 56017, Italy.
- Emma Center for Personalized Medicine, Department of Human Genetics, Amsterdam UMC, 1105 AZ, the Netherlands.
- Fondazione Pisana per La Scienza ETS, Pisa, 56017, Italy; Laboratory of Medical Oncology, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit, Amsterdam, 1081 HZ, the Netherlands;…
Förderung
- Fondazione Pisa
- KWF Kankerbestrijding
- Associazione Italiana per la Ricerca sul Cancro
- European Cooperation in Science and Technology
- AIRC Foundation for Cancer Research
Zitieren
APA
Rocco, M. A., Kirvaitytė, M., Lencioni, G., Mariani, S., McDonnell, L. A., Hussein, M., & Giovannetti, E. (2026). CRISPR-based diagnostics as a specificity layer for the early detection of pancreatic cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218851
Vancouver
Rocco MA, Kirvaitytė M, Lencioni G, Mariani S, McDonnell LA, Hussein M, et al. CRISPR-based diagnostics as a specificity layer for the early detection of pancreatic cancer. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218851
BibTeX
@article{Rocco2026,
author = {Rocco, Mafalda Angelica and Kirvaitytė, Milda and Lencioni, Giulia and Mariani, Stefano and McDonnell, Liam A and Hussein, Mouraya and Giovannetti, Elisa},
title = {CRISPR-based diagnostics as a specificity layer for the early detection of pancreatic cancer},
journal = {Cancer Letters},
year = {2026},
doi = {10.1016/j.canlet.2026.218851}
}
EUVIMED